(2-Methylanilino)thiourea is an organic compound with the chemical formula C8H10N2S. It is a white to yellowish solid that is soluble in water.
**Structure and Properties:**
* **Structure:** It consists of a thiourea moiety (NH2-CS-NH2) with a 2-methylanilino group (C6H4(CH3)NH-) attached to one of the nitrogen atoms.
* **Properties:**
* Molecular weight: 182.25 g/mol
* Melting point: 108-110 °C
* Boiling point: Not available
**Importance in Research:**
(2-Methylanilino)thiourea is a versatile compound with potential applications in various research areas, including:
* **Drug Discovery:**
* **Antimicrobial Activity:** It has shown significant antimicrobial activity against a range of bacteria, including Staphylococcus aureus and Escherichia coli. Its mechanism of action is thought to involve inhibition of bacterial growth by interfering with the synthesis of essential cellular components.
* **Anticancer Activity:** Some studies suggest that it possesses anticancer activity, particularly against breast cancer cells. Its potential as a cancer therapeutic agent is being investigated.
* **Materials Science:**
* **Polymer Chemistry:** It can be used as a monomer for the synthesis of novel polymers with potential applications in various fields, such as electronics and biomaterials.
* **Metal Coordination Chemistry:** It acts as a chelating agent, forming complexes with metal ions. This property makes it useful in the development of metal-organic frameworks (MOFs) and other coordination complexes with potential applications in catalysis, sensing, and drug delivery.
* **Analytical Chemistry:**
* **Spectrophotometry:** It can be used as a reagent in spectrophotometric methods for the determination of various analytes, including metal ions and organic compounds.
**Current Research and Future Prospects:**
Ongoing research focuses on exploring the potential applications of (2-methylanilino)thiourea in various fields, including:
* **Optimizing its antimicrobial activity and developing novel antimicrobial agents.**
* **Investigating its anticancer properties and developing targeted therapies for cancer treatment.**
* **Synthesizing new polymers and MOFs with unique properties and potential applications.**
* **Developing new analytical methods for the detection and quantification of analytes.**
The versatility and potential of (2-methylanilino)thiourea make it an exciting area of research with the potential to contribute to advancements in various disciplines.
**Note:** It is important to note that while (2-methylanilino)thiourea shows promise in research, it is still in the early stages of development. Further research is needed to understand its full potential and safety profile before it can be used in clinical applications.
ID Source | ID |
---|---|
PubMed CID | 1490896 |
CHEMBL ID | 1353091 |
CHEBI ID | 108936 |
SCHEMBL ID | 11750548 |
Synonym |
---|
nsc 97210 |
brn 0880437 |
smr000336171 |
MLS000764026 |
2-(2-methylphenyl)-1-hydrazinecarbothioamide |
STK039155 |
2-(2-methylphenyl)hydrazinecarbothioamide |
CHEBI:108936 |
(2-methylanilino)thiourea |
AKOS005083341 |
A833206 |
1-[(2-methylphenyl)amino]thiourea |
NCGC00246535-01 |
HMS2711H10 |
3-12-00-01882 (beilstein handbook reference) |
1P-072 |
[(2-methylphenyl)amino]thiourea |
20174-30-5 |
1-(o-tolyl)-3-thiosemicarbazide |
YRABENKRWXQGMK-UHFFFAOYSA-N |
CHEMBL1353091 |
SCHEMBL11750548 |
Q27187908 |
tolylthiosemicarbazid |
Class | Description |
---|---|
phenylhydrazines | Any member of the class of hydrazines carrying a phenyl substituent. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 1.1220 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
Chain A, Putative fructose-1,6-bisphosphate aldolase | Giardia intestinalis | Potency | 15.8114 | 0.1409 | 11.1940 | 39.8107 | AID2451 |
phosphopantetheinyl transferase | Bacillus subtilis | Potency | 50.1187 | 0.1413 | 37.9142 | 100.0000 | AID1490 |
GLS protein | Homo sapiens (human) | Potency | 11.2202 | 0.3548 | 7.9355 | 39.8107 | AID624170 |
TDP1 protein | Homo sapiens (human) | Potency | 21.8528 | 0.0008 | 11.3822 | 44.6684 | AID686978; AID686979 |
Microtubule-associated protein tau | Homo sapiens (human) | Potency | 17.7828 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 22.3872 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 11.2202 | 0.0355 | 20.9770 | 89.1251 | AID504332 |
lysosomal alpha-glucosidase preproprotein | Homo sapiens (human) | Potency | 11.2202 | 0.0366 | 19.6376 | 50.1187 | AID2100 |
DNA polymerase beta | Homo sapiens (human) | Potency | 63.0957 | 0.0224 | 21.0102 | 89.1251 | AID485314 |
DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 89.1251 | 0.0501 | 27.0736 | 89.1251 | AID588590 |
nuclear receptor ROR-gamma isoform 1 | Mus musculus (house mouse) | Potency | 10.6655 | 0.0079 | 8.2332 | 1,122.0200 | AID2546; AID2551 |
Vpr | Human immunodeficiency virus 1 | Potency | 35.4813 | 1.5849 | 19.6264 | 63.0957 | AID651644 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |